MediumEndocrinologyType 2 diabetes with cardiovascular and renal diseaseau-amcau-racp
A 68-year-old woman with long-standing type 2 diabetes and established coronary artery disease has an HbA1c of 8.4% (68 mmol/mol) despite maximal metformin therapy. eGFR is 55 mL/min/1.73 m² and she has microalbuminuria. According to contemporary Australian guidelines, which additional class of glucose-lowering medicine should be prioritised?